Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
FACT/GOG-NTX Version 4 - Get Ringing or Buzzing in My Ears	NCIT_C151230	[Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I get a ringing or buzzing in my ears.]
Fluzoparib	NCIT_C126274	[An orally available inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2, with potential antineoplastic activity. Upon oral administration, fluzoparib inhibits PARP 1 and 2 activity, which inhibits PARP-mediated repair of damaged DNA via the base excision repair (BER) pathway, enhances the accumulation of DNA strand breaks, promotes genomic instability, and leads to an induction of apoptosis. The PARP family of proteins catalyze post-translational ADP-ribosylation of nuclear proteins, which then transduce signals to recruit other proteins to repair damaged DNA. PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance.]
Anti-LAMP1 Antibody-drug Conjugate SAR428926	NCIT_C126275	[An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) conjugated, via the disulfide-containing cleavable linker N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-LAMP1 ADC SAR428926, the anti-LAMP1 monoclonal antibody moiety targets and binds to the cell surface antigen LAMP1. After antibody-antigen interaction and internalization, the SPDB linker is selectively cleaved by proteases in the cytosol and the DM4 moiety is released. DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting both cell division and cell growth of LAMP1-expressing tumor cells. LAMP1, overexpressed on a variety of cancer cells, plays a key role in cell-cell adhesion and migration. The SPDB linker is resistant to cleavage in the bloodstream, which may increase stability and reduce toxicity.]
Antineoplastic Antibody-Drug Conjugate	NCIT_C129823	[Any tumor-targeting antibody conjugated to a cytotoxic agent that exerts an antineoplastic effect.]
FACT/GOG-NTX Version 4 - I Have Trouble Buttoning Buttons	NCIT_C151231	[Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble buttoning buttons.]
Autologous HBV-specific TCR-redirected T-Lymphocytes	NCIT_C126270	[A preparation of human autologous T-lymphocytes transduced with a viral vector encoding for a T-cell receptor (TCR) specific for a human hepatitis B virus (HBV) surface antigen (HBsAg), with potential antineoplastic activity. Following administration, the autologous HBV antigen specific TCR-redirected autologous T-lymphocytes recognize and bind to the HBV antigen-positive cells, which induces cytotoxic T-lymphocyte (CTL)-mediated elimination of HBV antigen-positive cancer cells. HBV antigens are found on HBV-positive cells and HPV-induced hepatocellular carcinoma (HCC).]
Therapeutic Autologous Lymphocytes	NCIT_C28681	[A population of lymphocytes isolated from an individual, altered in vitro, and returned to the same individual for therapeutic purposes. (NCI04)]
T-cell Receptor-engineered T-cells	NCIT_C138180	[T-lymphocytes that have been engineered to express a modified antigen-specific T-cell receptor (TCR). In cancer therapy, the TCR-engineered T-cell recognizes a tumor-specific protein fragment complexed with major histocompatibility complex (MHC) molecules on the surface of the tumor cells and kills the tumor cell.]
PI3K p110beta/delta Inhibitor KA2237	NCIT_C126271	[A dual selective inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K-beta/delta), with potential antineoplastic activity. PI3K-beta/delta inhibitor KA2237 selectively inhibits the PI3K-beta and -delta isoforms and prevents their activation, which inhibits PI3K-beta/delta-mediated signal transduction pathways. This decreases proliferation and induces cell death in susceptible tumor cells. Unlike other isoforms of PI3K, PI3K-beta and -delta are overexpressed primarily in solid and hematological tumor cells and play crucial roles in tumor cell survival, and immunoregulation. The targeted inhibition of these PI3Ks allows this agent to potentially be more efficacious and less toxic than pan PI3K inhibitors, which also affect normal, healthy cells.]
FACT-L Version 4 - Trouble Meeting Needs of Family	NCIT_C151236	[Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.]
FACT-L Version 4 - I Have Pain	NCIT_C151237	[Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I have pain.]
FACT-L Version 4 - Bothered by Treatment Side Effect	NCIT_C151238	[Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I am bothered by side effects of treatment.]
FACT-L Version 4 - I Feel Ill	NCIT_C151239	[Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I feel ill.]
FACT/GOG-NTX Version 4 - Trouble Feeling Shape of Objects	NCIT_C151232	[Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble feeling the shape of small objects when they are in my hand.]
FACT/GOG-NTX Version 4 - I Have Trouble Walking	NCIT_C151233	[Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble walking.]
FACT-L Version 4 - I Have a Lack of Energy	NCIT_C151234	[Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I have a lack of energy.]
FACT-L Version 4 - I Have Nausea	NCIT_C151235	[Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I have nausea.]
FACT/GOG-NTX Version 4 - I Have Trouble Hearing	NCIT_C151229	[Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble hearing.]
PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1	NCIT_C126276	[A fusion protein consisting of a peptide sequence of human papillomavirus (HPV) type 16 E7 nuclear protein and fused to the Pseudomonas aeruginosa exotoxin A (PE) and a endoplasmic reticulum (ER) retention signal (KDEL), with potential antineoplastic activity. Upon administration of PE/HPV16 E7/KDEL fusion protein TVGV-1, the PE moiety binds to CD91 (LRP1) expressed on a variety of cells, including antigen-presenting cells such as dendritic cells (DCs), which facilitates the internalization, through endocytosis, of TVGV-1. Following endocytosis, this agent is proteolytically cleaved by the proteasome and the epitopes from the HPV E7 protein become bound to MHC-I molecules and are presented on the DC-cell surface. This facilitates a cytotoxic T-cell- mediated immune response against HPV16 E7 expressing-tumor cells. KDEL targets the fusion protein to the ER, which increases this agent's potential to be bound by MHC-I molecules; this increases the immune response against HPV16 E7-expressing cancer cells.]
Immunosuppressant	NCIT_C574